Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis-Reference-Cited by-同舟云学术

Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis

Published:2016-08-31 Issue:1 Volume:6 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Solé Cristina,Solà Elsa,Morales-Ruiz Manuel,Fernàndez Guerau,Huelin Patricia,Graupera Isabel,Moreira Rebeca,de Prada Gloria,Ariza Xavier,Pose Elisa,Fabrellas Núria,Kalko Susana G.,Jiménez Wladimiro,Ginès Pere

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep32341.pdf

Reference33 articles.

1. Tsochatzis, E. A., Bosch, J. & Burroughs, A. K. Liver cirrhosis. Lancet 383, 1749–1761, doi:10.1016/S0140-6736(14)60121-5 (2014).

2. Úbeda, M. et al. Critical role of the liver in the induction of systemic inflammation in rats with preascitic cirrhosis. Hepatology 52, 2086–2095, doi:10.1002/hep.23961 (2010).

3. Albillos, A., Lario, M. & Álvarez-Mon, M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol 61, 1385–1396, doi:10.1016/j.jhep.2014.08.010 (2014).

4. Chen, G. Y. & Nuñez, G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 10, 826–837, doi:10.1038/nri2873 (2010).

5. Kumar, H., Kawau, T. & Akiras S. Pathogen recognition by the innate immune system. Int Rev Immunol 30, 16–34 (2011).

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pre-treatment with tocilizumab reduces lipopolysaccharide-induced acute lung injury in biliary cirrhotic rats;European Journal of Pharmacology;2024-10

2. From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury;Hepatology;2024-02-14

3. The liver sinusoid in acute-on-chronic liver failure;Sinusoidal Cells in Liver Diseases;2024

4. Hepatorenal Syndrome—Novel Insights into Diagnostics and Treatment;International Journal of Molecular Sciences;2023-12-14

5. Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial;Hepatology Communications;2023-12